Modus Therapeutics Holding AB
99Z
Company Profile
Business description
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation, as well as states of anemia related to chronic inflammation, such as kidney diseases, through its patented polysaccharide, sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.
Contact
Olof Palmes gata 29 IV
Stockholm111 22
SWET: +46 850137000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,462.60 | 40.90 | 0.49% |
| CAC 40 | 7,743.75 | 49.31 | 0.64% |
| DAX 40 | 23,499.32 | 146.63 | 0.63% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,554.80 | 23.19 | 0.27% |
| HKSE | 22,867.74 | 91.82 | 0.40% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
| SSE Composite Index | 3,342.00 | 10.00 | -0.30% |